Replies to post #219452 on Avid Bioservices Inc (CDMO)

[Threes]

Well how about Blackrock also in attendance.
If they know the culprit and the future then we will look good in the end.
Blackrock got out just before black Monday and then reloads with even a bigger piece of PPHM then before.

Wonder where AF fits in this, he also was a little more then clairvoyant before black Monday.

If they were all in on the game they sure are brazen, the untouchables.

Blackrock timely sell/buy. and AF just could not resist putting out his inside info. to stroke his ego.


Only the shadow knows, and JB , CSM.


WHERE IS THE FBI/FDA/SEC !!!!

[Protector]

biopharm, a remarkable conclusion...!

For example: Lori Fink chair of Cancer Institute Advisory Board and would there be much political sway with her spouse Laurence Fink in the background and also on boards/medical related in NY areas...? I'll say one thing, when a Fink is Chairman of NYU Langone’s Laura and Isaac Perlmutter Cancer Center and brings in much monies in many areas and then many Docs associated with BMS and all are deeply rooted in other therapies, (certainly not PS Targeting that was developed by outsiders Peregrine Pharmaceuticals) then anything is possible and early stage clinical trial(s) Sabotaged back at CSM in Fargo? ....sounds like a very real possibility to me.

Remarkable even more in the light that in one of the CSM testimonies OR CSM lawyers filings (I don't remember which one) it was FINELY HINTED and SUGGESTED that PPHM operates under the assumptions things can only have gone wrong at CSM in FARGO, EXCLUDING all involvement possibilities of the treatment centres.

Now PERSONALLY (that is me in my head) I do EXCLUDE the treatment centres from any involvement (except for the occasional real human error that might have occurred, probably even didn't, but certainly would not explain the scale and systematic characteristics of the dose switching).

BUT I would not exclude a PART-TAKING role of some treatment centres with which others then obvious alliances might have existed. I do however, in that head of mine, not position this in the context of the DOSE SWITCHING activities but would rather think in the direction of the amount of censored patients and the UNDERLYING REASONS why they were censored.

I mean, a patients would be censored if he suddenly left the trial (during or just after treatment) and could not have been found back for follow-up? It doesn't take much in certain countries (and do not think as Africa to be the only corrupt place on Earth, feel free to put the US, Russia, China and Europe in that list) to find out from the Hospital WHO is part of the Bavituximab PII NSCLC trial. Once you have the names of the patients, and AFTER the treatment, it doesn't cost much incentive wise to pay someone to no longer show up for follow up. In Russia or Georgia I'd even see a Doctor be paid to pay the patient to disappear from the radar or to just not report any more claiming the patients doesn't show up any more.

In this way the statistical significance becomes more difficult to reach because the WORTH-FULL 'n' goes down. If, and this is IF, such thing happened it would NOW play in our advantage because it would mean that the relatively high # of censored patients, ON TOP OF THE DOSE SWITCHING, did not manage to impact the trial negatively and make it so that it wouldn't qualify for the FDA to NOT allow a PIII.

[nh]

Surely you don't mean Laurence D. Fink, Chairman and CEO, BlackRock, Inc. ? You mean the company that dumped millions of shares of PPHM prior to the run up in 2012, prior to the release of news of sabotage of PPHM's gold standard trial? The company that has amassed millions of shares again?

Oh, surely not.

Where o where is our SEC? Surely they will want some pay-to-play money from this one.